An Opportunity Missed: Biosimilars in the United States
Arthritis Rheumatol
.
2020 Jul;72(7):1046-1048.
doi: 10.1002/art.41280.
Epub 2020 May 10.
Authors
Guro L Goll
1
,
Tore K Kvien
1
Affiliation
1
Diakonhjemmet Hospital, Oslo, Norway.
PMID:
32270925
DOI:
10.1002/art.41280
No abstract available
Publication types
Editorial
Comment
MeSH terms
Biosimilar Pharmaceuticals*
Drug Approval
United States
United States Food and Drug Administration
Substances
Biosimilar Pharmaceuticals